Frank L. Meyskens, Jr., M.D., F.A.C.P.

Frank L. Meyskens, Jr., M.D., F.A.C.P. is Professor of Medicine and Biological Chemistry, Director of the Chao Family Comprehensive Cancer Center, and Senior Associate/Dean of Health Sciences for the College of Health Science at UC Irvine. He was originally recruited to UC Irvine in 1989 as Professor of Medicine and Biological Chemistry and to serve as Medical Director of Oncology Services and Chief of Hematology/Oncology with the mandate to develop a Cancer Center. He received his M.D. and interned at the University of California, San Francisco, and completed his Medical Oncology training at the National Institutes of Health, during which time he conducted molecular biology investigations in the Laboratory of Tumor Cell Biology. Since 1977, he has been continuously funded by the National Institutes of Health. Prior to UCI, Dr. Meyskens was at the Arizona Cancer Center at the University of Arizona where he served as Associate Director of Cancer Prevention and Control, from 1984 to 1989, and established one of the most successful Cancer Prevention Research Programs in the world. While at Arizona, he was Principal Investigator of the Vitamin A and Chemoprevention Program Project (PO1 CA 27502) and the PO1 CA41108 Program Project for the study of colon cancer and prevention. He has established a similar chemopreventive effort at UCI and is conducting phase I, II, III and IV chemopreventive trials supported by the NCI and NIH. His current major efforts also include accrual to a phase IIb trial of Bowman-Birk Inhibitor in oral leukoplakia, a phase IIb/III cohort of patients at risk for colon polyps treated with DFMO plus sulindac versus placebo, and a unique natural history, epidemiology and chemoprevention study of patients at high risk of prostate cancer based on familial background. All studies have extensive translational components and are funded by the National Cancer Institute. Additionally, for over 25 years he has conducted active clinical and laboratory research into the cellular and molecular mechanisms of transformation of human melanocyte and melanoma cells and he is recognized as one of the premier clinical and experimental oncologists concerned with melanoma.